All News

Dr P Seo answers audience questions…he does not check ANCA levels regularly as results do not impact his actions but may induce anxiety #Vasculitis #RNL2024 @RheumNow https://t.co/GV62DF7s3y

https://twitter.com/KDAO2011/status/1751622005172965610/photo/1

Dr. P Seo's summary slide on management of #vasculitis #RNL2024 @rheumnow https://t.co/cZLI6iz1sL

https://twitter.com/KDAO2011/status/1751620754469195915/photo/1

Dr. P Seo's Pearls for #Vasculitis: 1. Weekly or q2weeks SC TCZ is fine for newly diagnosed patients, but if pts relapse, use weekly TCZ. 2. oral steroids perform fine (no need to do IV pulse) even in pts with vision changes 3. taper steroids over 3-4 months @rheumnow #RNL2024

The great unknown with tocilizumab in GCA, do you stop, how do you stop, etc. @philseo approach. I'm not as brave! Usually park at every other week dosing @RheumNow #RNL2024 https://t.co/y7mg57mWND

https://twitter.com/RichardPAConway/status/1751618632881263023/photo/1

Dr @anisha_dua's takehome points for treating GPA in 2024 *RTX and CYC are both effective followed by RTX at least 500mg q 6 mo for at least 2 years *PLEX not generally used, but may be effective in preventing ESKD *Rapid GC tapering may not be suitable for all pts *Avacopan is… https://t.co/haI19Sgpmu https://t.co/jhjXLwd0Uw

Contrasing ACR/VF and EULAR GPA guidelines from @anisha_dua @RheumNow #RNL2024 https://t.co/RLJx9fJHGk

https://twitter.com/RichardPAConway/status/1751609824973139984/photo/1

@anisha_dua reviews differences between EULAR vs ACR Vasculitis guidelines #RNL2024 @RheumNow https://t.co/1aIbnX5KBI

https://twitter.com/KDAO2011/status/1751607655934709827/photo/1

@anisha_dua reviews GPA management in 2024. Here are your ACR/VF 2021 and EULAR 2022 guideline updates. Review these regimen options for your patients. #RNL2024 @RheumNow https://t.co/SvQoe0YKKV

https://twitter.com/uptoTate/status/1751607745214587184/photo/1

Combining results of urinary IL16, PR3, CD163 at 12 months best predicts kidney function protection at 3 years - @andreafava #RNL2024 @rheumnow https://t.co/0XV0MrhL1F

https://twitter.com/KDAO2011/status/1751385890633465896/photo/1

ICYMI @eular_org 2023 SLE Treatment guidelines https://t.co/BkGhwQtSor @rheumnow #RNL2024 https://t.co/troJ9D6AGm

Treatment of SLE. EULAR guidelines via @Kahlenberglab @RheumNow #RNL2024 https://t.co/a5lWfRLuh3

https://twitter.com/RichardPAConway/status/1751378550857388344/photo/1

Lupus has many flavors. If we are better able to sort them, we might be more better at finding effective treatments. @rheumnow #RNL2024 @DrDavidKarp https://t.co/rklqnA8Ur6

https://twitter.com/KDAO2011/status/1751374449121562884/photo/1

"Any vacuolar interface dermatitis will respond to a JAKi" - Dr. B Strober noted JAKi will work for cutaneous lupus #RNL2024 @rheumnow

Face and neck vitiligo also responds to topical ruxolitinib. Dr. Strober #RNL2024 @RheumNow https://t.co/6N6A3Yq7RE

https://twitter.com/uptoTate/status/1751348178459226441/photo/1

Impressive results for alopecia totalis with baricitinib – Dr. Bruce Strober #RNL2024 @rheumnow https://t.co/OA0tpdRum2

Clinical pearl! Consider topical ruxolitinib for your AD patients. Dr. Strober at #RNL2024 @RheumNow https://t.co/Sxwvn1lAXB

https://twitter.com/uptoTate/status/1751346813494346091/photo/1

The differences do appear to relate to actual treatment specific differential response. As well as no difference with JAKi, there seems to be no difference in placebo response @lihi_eder @RheumNow #RNL2024 https://t.co/7H4KRvd6WG

https://twitter.com/RichardPAConway/status/1751305570009690587/photo/1

Did you know? There is very limited reporting of sex-disaggregated RCT results, data necessary from an FDA standpoint. Dr. L. Eder points out the importance of this data from a clinical standpoint. Let's do better! #RNL2024 @RheumNow @lihi_eder https://t.co/3FETZZWt0B

https://twitter.com/uptoTate/status/1751303618328691121/photo/1

This is the risk. We have to be aware and better at this in order to serve our female patients better @lihi_eder @RheumNow #RNL2024 https://t.co/7JIDtlSGXh

https://twitter.com/RichardPAConway/status/1751303305006141484/photo/1

Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI

https://twitter.com/RichardPAConway/status/1751292231988683107/photo/1

Topics

All News

Do you get our email newsletter?